Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

800571

	registered interest
	date	04/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neuromuscular Disorders
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the (a) extent and (b) effect on patient care of variation in specialist services for multiple sclerosis and Parkinson's among clinical commissioning groups in England.
	tabling member constituency	York Outer
	tabling member printed	Julian Sturdy
	uin	117192
	answer	answer is ministerial correction date of answer 12/12/2017 answer text <p>We know that variation exists between clinical commissioning groups (CCGs) in the provision of care for neurological conditions, such as Parkinson’s disease and multiple sclerosis. Whilst it is right that CCGs have autonomy to shape services for local populations, there is a range of work ongoing at a national level to identify unwarranted variation in order to drive improvement, including:</p><p> </p><p>- Through the RightCare programme, which was rolled out to every CCG in 2016/17, NHS England provides practical support to commissioners to tackle unwarranted variation and identify improvements and savings, including for neurological services;</p><p>- Public Health England’s Neurology intelligence network collates and interprets data on adult neurological conditions to provide intelligence for the National Health Service, policy makers, and clinicians; and</p><p>- The Getting it Right First Time programme, supported by NHS Improvement, expanded earlier in 2017 to include neurology and will soon provide insight to demonstrate the value of better neurological services both in hospitals and in the community.</p><p> </p><p>NHS England will continue to work with the Neurological Alliance (an umbrella organisation for neurological condition charities) to support the new national Neurology Advisory Group (NAG), led by consultant neurologist Professor Adrian Williams. The NAG brings together system partners, professional bodies stakeholders to align work to improve neurological care, and has working to understand how best to utilise new and emerging data in services and outcomes. More information on national initiatives to reduce unwarranted variation and drive improvement can be found at the following links:</p><p> </p><p><a href="http://www.england.nhs.uk/rightcare/" target="_blank">www.england.nhs.uk/rightcare/</a></p><p> </p><p><a href="http://www.gov.uk/guidance/neurology-data-and-analysis-a-guide-for-health-professionals" target="_blank">www.gov.uk/guidance/neurology-data-and-analysis-a-guide-for-health-professionals</a></p><p> </p><p><a href="http://gettingitrightfirsttime.co.uk/" target="_blank">gettingitrightfirsttime.co.uk/</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 117193 question first answered 12/12/2017 17:07:27 answering member 4067 label Biography information for Steve Brine
	tabling member	4079 label Biography information for Julian Sturdy

800572

	registered interest
	date	04/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neuromuscular Disorders
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment his Department has made of the potential for improved specialist services for multiple sclerosis and Parkinson's delivering significant savings for the NHS; and if he will make a statement.
	tabling member constituency	York Outer
	tabling member printed	Julian Sturdy
	uin	117193
	answer	answer is ministerial correction date of answer 12/12/2017 answer text <p>We know that variation exists between clinical commissioning groups (CCGs) in the provision of care for neurological conditions, such as Parkinson’s disease and multiple sclerosis. Whilst it is right that CCGs have autonomy to shape services for local populations, there is a range of work ongoing at a national level to identify unwarranted variation in order to drive improvement, including:</p><p> </p><p>- Through the RightCare programme, which was rolled out to every CCG in 2016/17, NHS England provides practical support to commissioners to tackle unwarranted variation and identify improvements and savings, including for neurological services;</p><p>- Public Health England’s Neurology intelligence network collates and interprets data on adult neurological conditions to provide intelligence for the National Health Service, policy makers, and clinicians; and</p><p>- The Getting it Right First Time programme, supported by NHS Improvement, expanded earlier in 2017 to include neurology and will soon provide insight to demonstrate the value of better neurological services both in hospitals and in the community.</p><p> </p><p>NHS England will continue to work with the Neurological Alliance (an umbrella organisation for neurological condition charities) to support the new national Neurology Advisory Group (NAG), led by consultant neurologist Professor Adrian Williams. The NAG brings together system partners, professional bodies stakeholders to align work to improve neurological care, and has working to understand how best to utilise new and emerging data in services and outcomes. More information on national initiatives to reduce unwarranted variation and drive improvement can be found at the following links:</p><p> </p><p><a href="http://www.england.nhs.uk/rightcare/" target="_blank">www.england.nhs.uk/rightcare/</a></p><p> </p><p><a href="http://www.gov.uk/guidance/neurology-data-and-analysis-a-guide-for-health-professionals" target="_blank">www.gov.uk/guidance/neurology-data-and-analysis-a-guide-for-health-professionals</a></p><p> </p><p><a href="http://gettingitrightfirsttime.co.uk/" target="_blank">gettingitrightfirsttime.co.uk/</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 117192 question first answered 12/12/2017 17:07:27 answering member 4067 label Biography information for Steve Brine
	tabling member	4079 label Biography information for Julian Sturdy

819992

	registered interest
	date	10/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will introduce a national minor ailments scheme as part of the Pharmacy Integration Fund, and if he will make a statement.
	tabling member constituency	York Outer
	tabling member printed	Julian Sturdy
	uin	122064
	answer	answer is ministerial correction date of answer 18/01/2018 answer text <p>Minor ailment services are commissioned locally by the National Health Service according to need. The purpose of the Pharmacy Integration Fund (PhIF) is to try out and evaluate new ways of integrating pharmacists and community pharmacy into the wider health care system. National commissioning of NHS pharmaceutical services is arranged through the Community Pharmacy Contractual Framework. In December 2017, under the PhIF, NHS England commenced a pilot urgent minor illness care pathway of direct referral from NHS 111 to community pharmacy. The outcome of this pilot will inform future commissioning decisions.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/01/2018 14:11:29 answering member 4067 label Biography information for Steve Brine
	tabling member	4079 label Biography information for Julian Sturdy

809129

	registered interest
	date	19/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Fees and Charges
	house id	1
	legislature	25259 pref label House of Commons
	question text	What recent assessment he has made of trends in the level of fines in relation to dental and prescription charges.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	903036
	answer	answer is ministerial correction date of answer 19/12/2017 answer text <p>The NHS Business Services Authority (NHS BSA) issues penalty charge notices (PCNs) for incorrect claims for exemption from National Health Service dental and prescription charges.</p><p>To ensure the integrity of the exemption system the NHS BSA has recently increased the number of checks. In 2016/17, 365,181 PCNs for dental charges and 975,065 for prescription charges were issued. This represents an increase of 90.11% and 90.23%, respectively, on 2015/16. There is a clear process for patients to appeal a PCN if they believe it is unjustified.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/12/2017 17:09:22 answering member 4067 label Biography information for Steve Brine
	tabling member	4471 label Biography information for Rachael Maskell

820695

	registered interest
	date	11/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cervical Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the take-up rate for cervical screening in (a) England, (b) North Yorkshire and (c) York was in 2017.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	122113
	answer	answer is ministerial correction date of answer 16/01/2018 answer text <p>The National Health Service Cervical Screening Programme measures coverage rather than uptake rate. NHS England is responsible for monitoring the coverage rates for cervical screening in all age groups and is committed to improving coverage and reducing variation between all age groups.</p><p> </p><p>Data are provided by NHS Digital and are available at:</p><p> </p><p><a href="https://digital.nhs.uk/article/7035/Cervical-screening-programme-coverage" target="_blank">https://digital.nhs.uk/article/7035/Cervical-screening-programme-coverage</a></p><p> </p><p>General practitioner/clinical commissioning group level coverage is available at:</p><p> </p><p><a href="http://digital.nhs.uk/catalogue/PUB24229" target="_blank">http://digital.nhs.uk/catalogue/PUB24229</a></p><p> </p><p>The percentage of coverage for each area requested as at the end of 2016-17 is: England 72.0%; North Yorkshire 78.1%; York 73.0%.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/01/2018 11:48:21 answering member 4067 label Biography information for Steve Brine
	tabling member	4471 label Biography information for Rachael Maskell

810590

	registered interest
	date	21/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Public Health England
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the timetable is for the implementation of the recommendations of the McNeil Review into cancer patient data at Public Health England (PHE), and what effect that implementation will have of PHE's adherence to NHS rules on consent.
	tabling member constituency	West Lancashire
	tabling member printed	Rosie Cooper
	uin	120935
	answer	answer is ministerial correction date of answer 08/01/2018 answer text <p>The McNeil Review into Public Health England’s (PHE) data collection and data management functions considered whether, how and when these should be transferred to NHS Digital. It identified four tranches of data, based on the complexity of the processes involved in the collection and quality assurance of the data and recommended that cancer registration be considered within tranche three and only after the earlier tranches had been completed; this is expected to take at least three years. PHE and NHS Digital are currently scoping the work programme to implement the review’s recommendations. PHE will continue to process cancer data in line with current legal gateways and the National Health Service rules on consent, taking into account any changes that may arise with emerging legislative and policy frameworks.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 08/01/2018 16:44:38 answering member 4067 label Biography information for Steve Brine
	tabling member	1538 label Biography information for Rosie Cooper

819110

	registered interest
	date	09/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Energy Drinks: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health what assessment he makes of the health effects of energy drink products on children aged 16 and under.
	tabling member constituency	West Lancashire
	tabling member printed	Rosie Cooper
	uin	121787
	answer	answer is ministerial correction date of answer 15/01/2018 answer text <p>Energy drinks can be high in caffeine and sugar. Based on the current evidence on the safety of caffeine, the Food Standard Agency advises that children, or other people sensitive to caffeine, should consume caffeine only in moderation.</p><p> </p><p>In its review of the evidence on “Carbohydrates and Health” (2015), the Scientific Advisory Committee on Nutrition (SACN) concluded that the consumption of sugar-sweetened beverages, as compared with non-calorically sweetened beverages, results in greater weight gain and increases in body mass index. Consuming too many sugary drinks can also cause tooth decay. In light of these findings, SACN recommended that the consumption of sugar-sweetened beverages (for example, sugary fizzy drinks, soft drinks and squash) should be minimised by both children and adults.</p><p> </p><p>Key measures in our world-leading childhood obesity plan, launched in August 2016, include the soft drinks industry levy and sugar reduction and wider reformulation programme, which will encourage the food and drink industry to reduce the amount of sugar in products popular with children, including energy drinks.</p><p> </p><p>The Government will continue to monitor the situation and any new emerging scientific evidence on the consumption of energy drinks.</p><p> </p><p>“Carbohydrates and Health” is available at:</p><p> </p><p><a href="http://www.gov.uk/government/publications/sacn-carbohydrates-and-health-report" target="_blank">www.gov.uk/government/publications/sacn-carbohydrates-and-health-report</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 121788 question first answered 15/01/2018 11:56:59 answering member 4067 label Biography information for Steve Brine
	tabling member	1538 label Biography information for Rosie Cooper

819111

	registered interest
	date	09/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Energy Drinks: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans the Government has to restrict the sale of energy drink products to children under 16.
	tabling member constituency	West Lancashire
	tabling member printed	Rosie Cooper
	uin	121788
	answer	answer is ministerial correction date of answer 15/01/2018 answer text <p>Energy drinks can be high in caffeine and sugar. Based on the current evidence on the safety of caffeine, the Food Standard Agency advises that children, or other people sensitive to caffeine, should consume caffeine only in moderation.</p><p> </p><p>In its review of the evidence on “Carbohydrates and Health” (2015), the Scientific Advisory Committee on Nutrition (SACN) concluded that the consumption of sugar-sweetened beverages, as compared with non-calorically sweetened beverages, results in greater weight gain and increases in body mass index. Consuming too many sugary drinks can also cause tooth decay. In light of these findings, SACN recommended that the consumption of sugar-sweetened beverages (for example, sugary fizzy drinks, soft drinks and squash) should be minimised by both children and adults.</p><p> </p><p>Key measures in our world-leading childhood obesity plan, launched in August 2016, include the soft drinks industry levy and sugar reduction and wider reformulation programme, which will encourage the food and drink industry to reduce the amount of sugar in products popular with children, including energy drinks.</p><p> </p><p>The Government will continue to monitor the situation and any new emerging scientific evidence on the consumption of energy drinks.</p><p> </p><p>“Carbohydrates and Health” is available at:</p><p> </p><p><a href="http://www.gov.uk/government/publications/sacn-carbohydrates-and-health-report" target="_blank">www.gov.uk/government/publications/sacn-carbohydrates-and-health-report</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 121787 question first answered 15/01/2018 11:56:59 answering member 4067 label Biography information for Steve Brine
	tabling member	1538 label Biography information for Rosie Cooper

800513

	registered interest
	date	04/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Breast Cancer: Biosimilar Medicines
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether NHS England has provided any guidance to hospital trusts and clinicians on the introduction of a biosimilar of Herceptin (trastuzumab) for breast cancer.
	tabling member constituency	West Ham
	tabling member printed	Lyn Brown
	uin	117134
	answer	answer is ministerial correction date of answer 12/12/2017 answer text <p>A final date for the availability of a biosimilar of Herceptin (trastuzumab) has yet to be agreed. Therefore NHS England has not yet issued any guidance on the introduction of a biosimilar of Herceptin (trastuzumab) for breast cancer. However, NHS England has discussed the introduction and uptake of biosimilar trastuzumab with the Cancer Vanguard. The Vanguard is a group of National Health Service trusts looking at developing new models of care and providing replicable models for cancer care nationally that will act as blueprints for the NHS.</p><p> </p><p>The Cancer Vanguard will provide guidance and supporting documentation to hospital trusts and clinicians in the same way that documents were provided to support the introduction of biosimilar rituximab. Once a firm date is known, NHS trusts will be contacted regarding the availability of biosimilar trastuzumab and what they must do to ensure uptake. This will include linkages to the supporting documents issued by the Vanguard.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/12/2017 17:11:26 answering member 4067 label Biography information for Steve Brine
	tabling member	1583 label Biography information for Ms Lyn Brown

800913

	registered interest
	date	05/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Breast Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what discussions his Department has had with NHS England on whether breast cancer patients who currently receive Herceptin (trastuzumab) in the subcutaneous formulation will be included in their ambition for 80 per cent of existing patients being on the best value biological medicine within 12 months.
	tabling member constituency	West Ham
	tabling member printed	Lyn Brown
	uin	117472
	answer	answer is ministerial correction date of answer 13/12/2017 answer text <p>Through its Medicines Value Programme, NHS England aims to deliver best value for medicines used in the National Health Service. Use of best value biologics is part of this programme which will drive rapid uptake of biosimilar medicines in the NHS. Trastuzumab is currently available as two products – one for intravenous (IV) use and the other for subcutaneous use. We are expecting several biosimilars of the IV preparation to be available sometime in 2018. As part of the medicines value programme we expect 80% uptake of the best value biologic within 12 months – this applies only to the IV preparation.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/12/2017 15:25:02 answering member 4067 label Biography information for Steve Brine
	tabling member	1583 label Biography information for Ms Lyn Brown